A 2-Year, Multi-Center, Phase II, Open-Label, Fixed-Dose, Randomized Comparative Trial Of Azacitidine, With Or Without Deferasirox In Patients With Hi
Posted Date: May 15, 2019
- Investigator: Stephen Medlin
- Type of Study: Drug
The purpose of this study is to learn if combining the two drugs, deferasirox (Exjade?) and azacitidine (Vidaza?), is safe and has beneficial effects in people who have Int-2 or High Risk myelodysplastic syndrome (MDS). Deferasirox is an oral medicine (tablet) used to treat iron overload due to bloo
Criteria:
To Be Eligible To Participate, Patients Must Have Been Diagnosed With Higher Risk Myelodysplastic Sy
Keywords:
Mds, Myelodysplastic Synd, Cicl067aus47, Bone Marrow, Cancer
For More Information:
Uc Cancer Center
513-584-7698
kastla@uc.edu